TAD011

TAD011 is a novel, small molecule selective inhibitor of Fibroblast Growth Factor Receptors (FGFR), specifically targeting FGFR1, FGFR2, and FGFR3. Developed by Tianjin Pharmaceutical Co., Ltd., it is designed to treat advanced solid tumors that harbor FGFR genetic alterations, such as gene amplifications, mutations, or fusions. By inhibiting the tyrosine kinase activity of FGFR, TAD011 blocks downstream signaling pathways, including the RAS-MAPK and PI3K-AKT cascades, which are critical drivers of tumor cell proliferation, survival, and angiogenesis. The drug is currently undergoing Phase 1 clinical evaluation in patients with advanced solid tumors to assess its safety, tolerability, and preliminary efficacy.